Form 8-K - Current report:
SEC Accession No. 0001193125-24-260421
Filing Date
2024-11-18
Accepted
2024-11-18 07:01:29
Documents
13
Period of Report
2024-11-12
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d874889d8k.htm   iXBRL 8-K 41120
  Complete submission text file 0001193125-24-260421.txt   164567

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA syrs-20241112.xsd EX-101.SCH 2845
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE syrs-20241112_lab.xml EX-101.LAB 17236
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syrs-20241112_pre.xml EX-101.PRE 10809
15 EXTRACTED XBRL INSTANCE DOCUMENT d874889d8k_htm.xml XML 3499
Mailing Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140
Business Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140 617-744-1340
Syros Pharmaceuticals, Inc. (Filer) CIK: 0001556263 (see all company filings)

EIN.: 453772460 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37813 | Film No.: 241469740
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)